Tenax Therapeutics, Inc. (TENX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Tenax Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing novel cardiopulmonary therapies, specifically targeting pulmonary hypertension. The company is currently advancing its lead candidate, levosimendan (TNX-103), through the Phase 3 LEVEL clinical trial and preparing for a second global Phase 3 study (LEVEL-2). This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(10.8) million | $(21.3) million | $(7.4) million |
| Operating Expenses | $11.8 million | $23.1 million | $7.6 million |
| Research & Development | $6.1 million | $11.8 million | $5.0 million |
| General & Administrative | $5.7 million | $11.3 million | $2.6 million |
| Cash and Cash Equivalents (End of Period) | $105.5 million | $105.5 million | $9.4 million |
| Working Capital | $103.3 million | $103.3 million | $8.9 million |
| Stock-Based Compensation (YTD) | N/A | $8.8 million | $0.1 million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses for the six months ended June 30, 2025, increased by 205% compared to the same period in 2024. This was driven by a 136% increase in R&D expenses due to the expansion of the Phase 3 LEVEL trial and initiation of LEVEL-2, and a 340% increase in G&A expenses.
- Significant Stock-Based Compensation: Non-cash stock-based compensation expense surged to $8.8 million for the six months ended June 30, 2025, compared to $0.1 million in the prior year period. This increase is attributed to option grants in December 2024 and new grants in early 2025.
- Capital Position: Cash and cash equivalents increased from $9.4 million at June 30, 2024, to $105.5 million at June 30, 2025. This improvement resulted from a $23.2 million net raise in the March 2025 private placement and proceeds from the August 2024 offering.
- Interest Income: Interest income increased significantly to $1.9 million for the six months ended June 30, 2025, compared to $0.2 million in the prior year, reflecting higher cash balances from recent financings.
Guidance, Outlook, and Risks
- Clinical Outlook: The company expects to complete enrollment of 230 patients in the Phase 3 LEVEL study in the first half of 2026. The LEVEL-2 trial is on track to commence in 2025.
- Liquidity: Management believes current resources ($105.5 million) are sufficient to fund operations through 2027. Future capital requirements depend on clinical trial progress and regulatory approvals.
- Risks: The company has an accumulated deficit of $336.1 million and expects to continue incurring losses. Success depends on the outcome of clinical trials, regulatory approvals, and the ability to secure additional funding if needed. There are no material pending legal proceedings.
- Contingencies: The company holds a license with Orion Corporation for levosimendan, which includes potential milestone payments totaling up to $45.0 million upon commercialization and regulatory approvals. No liabilities have been recorded as milestones have not been met.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $105.5 million cash balance against the projected burn rate through 2027, considering the high stock-based compensation expenses.
- Clinical Milestones: Monitor patient enrollment rates for the LEVEL trial and the commencement timeline for the LEVEL-2 trial.
- Dilution Risk: Review the outstanding pre-funded warrants (35.4 million) and warrants (19.7 million) and their potential impact on share count upon exercise.
- Expense Management: Assess the trajectory of R&D and G&A expenses, particularly the impact of stock-based compensation on future net loss figures.
- Regulatory Path: Track the status of the Phase 3 trials and any updates regarding the FDA review process for levosimendan in pulmonary hypertension.